Left ventricular-assist device

Cardiac transplantation is one option for patients with severe heart failure. Candidates for cardiac transplantation generally present with New York Heart Association (NYHA) class III or IV symptoms and have an ejection fraction of less than 25%.1,3 The general indications for cardiac transplantation include rapidly declining cardiac function and a projected 1-year mortality rate of greater than 75%. Mechanical support with an implantable left ventricular assist device may be appropriate while patients await the availability of a viable organ.1,3 Some additional reasons for heart transplant include ... [Pg.830]

Wohlschlaeger J, Schmitz KJ, Schmid C, Schmid KW, Keul P, Takeda A, et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD) a review of the morphological and molecular changes. Cardiovasc Res 2005 68 376-386. [Pg.90]

Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998 98 656-662... [Pg.90]

Barbone A, Holmes JW, Heerdt PM, The AH, Naka Y, Joshi N, Daines M, Marks AR, Oz MC, Burkhoff D. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure a primary role of mechanical unloading underlying reverse remodeling. Circulation 2001 104 670-675... [Pg.90]

Hetzer R, Muller JH, Weng YG, Loebe M, Wallukat G. Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy. J Thorac Cardiovasc Surg 2000 120 843-853... [Pg.90]

Yacoub MH. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J 2001 22 534-540... [Pg.90]

Vranckx P, Foley DP, Feijter PJ, Vos J, Smits P, Serruys PW. Clinical introduction of the Tandem-heart, a percutaneous left ventricular assist device, for circulatory support during high-risk percutaneous coronary intervention. Internat J Cardiovasc Intervent 2003 5 35-39... [Pg.92]

Radovancevic B, Vrtovec B, Frazier OH. Left ventricular assist devices an alternative to medical therapy for end-stage heart failure. Cwr Opin Cardiol 2003 18 210-214. [Pg.121]

Current long-term mechanical support devices such as left ventricular assist devices (LVADs) require use of the heart lung machine and extensive surgery. The... [Pg.134]

In recipients of left ventricular assist devices awaiting cardiac transplantation treated with intravenous immunoglobulin, clinical manifestations of immune complex... [Pg.1724]

John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N, Edwards N, Rose E, Oz M, Itescu S. Intravenous immunoglobuhn reduces anti-HLA allo-reactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999 100(Suppl 19) II229-35. [Pg.1729]

C. M. Ballantyne, M. S. Verani, H. D. Short, C. Hyatt, G. P. Noon, Delayed recovery of severely stunned myocardium with the support of a left ventricular assist device after coronary artery bypass graft surgery, J Am Coll Cardiol 10, 710-712 (1987). [Pg.190]

Despite all these efforts, patients continue to die awaiting transplant. In 2001, over 6000 people died on transplant waiting lists. While renal dialysis may be used for an extended period of time to partially replace the function of the kidneys, such options are not readily available for all liver and heart transplant candidates. Hepato-cyte transplantation and artiflcal liver support are areas of research as alternatives or bridges to liver transplantation. Left-ventricular assist devices (LVADs) are now used commonly as a bridge to transplantation for many heart transplant candidates. [Pg.1613]

Advances in numerous areas have allowed marked increases in survival times of artificial heart device (AHD) and left ventricular assist device (LVAD) experiments. Successful clinical trials employing LVAD s for temporary post-operative assistance after coronary surgical procedures have been reported by several centers (1). As clinical use of circulatory assist devices progresses, longer term (i.e., 3-4 months) implantations will be needed requiring not only initial surface hemocompatibility, but also long-term surface inertness or stability. [Pg.392]

There is a lack of good detailed pathologic studies performed on heart valves prostheses recovered at surgery and/or autopsy. The lack of such studies will hinder the progress and development of not only better heart valve prostheses, but also other future artificial devices such as left ventricular assist devices and the total artificial heart. [Pg.142]

Since 1970 biolized materials have been utilized in our cardiac prostheses. Long term survival of TAH (total artificial heart) and LVAD (left ventricular assist device) implanted in animals has shown successful application of these materials without the use of anticoagulants (29). [Pg.168]

Zhou L, Armstrong G.P, Medvedev A.L., Smith W.A., Golding L.A., and Thomas J.D. 1999. Numeric modeling of the cardiovascular system with a left ventricular assist device. ASAIO J. 45 83-89. [Pg.171]

Left ventricular assist devices Prosthetic devices to assist the left ventricle in pumping blood. [Pg.732]

Tarbell, J.M., Gunishan, J.R, Geselowitz, D.B., Rosenberg, G Shung, K.K., and Pierce, W.S. 1986. Pulsed ultrasonic Doppler velocity measurements inside a left ventricular assist device. ASME J. Biomech. Eng. 108 232-238. [Pg.737]

Cardiovascular disease, namely, coronary artery disease, remains the leading cause of death in the developed nations. Over the last few years, MEMS sensors have advanced the understanding of blood flow, namely, fluid shear stress, in arterial circulation. Fluid shear stress is defined as the frictional force acting tangentially on the surface of a blood vessel wall. Furthermore, the measurement of wall shear stress is important to study the durability of prosthetic valves and to monitor thrombosis or blood clots in cardiopulmonary bypass machines, artificial hearts, and left ventricular assist devices. Luminal shear stress measurement predicts the development of atherosclerotic plaque in patients at risk for acute heart attacks. In this context, the application of microscale hot-wire anemometry bridges fluid mechanics of blood flow with vascular biology. [Pg.1784]

Vascular grafts and patches, as well as heart valves, are among the oldest of cardiovascular implants. More recently, permanent internal devices include pacemakers, defibrillators, stents, left ventricular assist devices, and artificial hearts. [Pg.329]

Heath, M. J. S., and Dickstein, M. L., Perioperative management of the left ventricular assist device recipient, ... [Pg.531]

Kasirajan, V., McCarthy, P. M., Hoercher, K. J., Starling, R. C., Young, J. B., Banbury, M. K., and Smedira, N. G., Clinical experience with long-term use of implantable left ventricular assist devices indications, implantation, and outcomes, Semin. Thorac. Cardiovasc. Surg., 2000 12(3) 229-237. [Pg.532]

McCarthy, P. M., and Hoercher, K., Clinically available intracorporeal left ventricular assist devices, Prog. [Pg.533]

Cardiovascular In an unusual case local anesthetics used for interscalene plexus block caused cardiogenic shock requiring management by implantation of a left ventricular assist device [3 ]. [Pg.209]

Samuels LE, Casanova-Ghosh E, Droogan C. Cardiogenic shock associated with loco-regional anesthesia rescued with left ventricular assist device implantation. J Cardiothorac Surg 2010 5 126. [Pg.217]

Fig. 11.8 Stepwise algorithm for management of heart failure patients who are nonresponders to CRT. AV = atrioventricular CXR = chest X-ray EKG = electrocardiogram Htx = heart transplant LV = left ventricular LVAD = left ventricular assist device MR = mitral regurgitation RV = right ventricular VV = interventricular. Cardiac ischemia is evaluated in patients with ischemic cardiomyopathy. Evidence of dyssynchrony includes septal to posterior wall motion delay > 130ms, intraventricular mechanical delay >40ms, and tissue Doppler imaging > 65 ms. (Reproduced witih permission from Aranda JM, Woo GW, Schofield RS, et al. J Am Coll Cardiol 2005 46 2193-8.)...

Yang M, Zang Z, Hahn C, Laroche G, King MW, Guidoin R. Totally implantable artificial hearts and left ventricular assist devices selected impermeable polycarbonate urethane to manufacture ventricles. J Biomed Mater Res 1999 48(1) 13-23. [Pg.167]

Frazier O, Gemmato C, Myers TJ, Gregoric ID, Radovancevic B, Loyalka P, et al. Initial clinical experience with the Heartmate II axial-flow left ventricular assist device. Tex Heart Inst J 2007 34(3) 275. [Pg.313]

Left ventricular assist devices Support heart function and blood flow... [Pg.351]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...